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HER2-positive breast cancer has long proven to be a clinically distinct class of breast cancers for
which several targeted therapies are now available. However, resistance to the treatment asso-
ciated with specific gene expressions or mutations has been observed, revealing the underlying
diversity of these cancers. Therefore, understanding the full extent of the HER2-positive disease
heterogeneity still remains challenging. Here we carry out an in-depth genomic characterization of
64 HER2-positive breast tumour genomes that exhibit four subgroups, based on the expression
data, with distinctive genomic features in terms of somatic mutations, copy-number changes or
structural variations. The results suggest that, despite being clinically defined by a specific gene
amplification, HER2-positive tumours melt into the whole luminal–basal breast cancer spectrum
rather than standing apart. The results also lead to a refined ERBB2 amplicon of 106 kb and show
that several cases of amplifications are compatible with a breakage–fusion–bridge mechanism.
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T
wo main classes of breast cancer (BC) are distinguished by
the expression of hormone receptors (HR); namely
oestrogen receptor (ER) and progesterone receptor (PR).
HR-positive breast cancers have a better prognosis than HR-
negative breast cancers. This classification is helpful in clinic but
the classes are still greatly heterogeneous. Transcriptomic
analyses have identified intrinsic molecular subtypes differing
by their expression programs, including luminal A and B, basal
and HER2-enriched subtypes1. Schematically, luminal breast
cancers express HR while basal breast cancers do not. Because of
this heterogeneity, due to various cell-of-origins and molecular
alterations, the response of breast cancer patients to therapy is
variable and difficult to predict2. Conversely, molecular
alterations represent potential therapeutic targets. Amplification
of the human epidermal growth factor receptor ERBB2/HER2
gene, located in chromosomal region 17q12 occurs in around
15% of breast cancers and defines the category of clinical HER2-
positive breast cancers. Overexpression of the ERBB2/HER2
protein kinase receptor has enabled patients with HER2-positive
tumour to benefit from antibody-based (for example,
trastuzumab) and anti-kinase-based (for example, lapatinib)
therapies that target this receptor3–7. These therapies, in use
these last 15 years, have completely changed the prognosis of
HER2-positive tumours. However, HER2-positive breast cancers
are heterogeneous. They may be included in the HER2-enriched
or luminal molecular subtypes, depending on whether they
express ER, and this has a consequence on their response to
targeted therapies. Indeed, several clinical trials have pointed out
the variability in efficacy of trastuzumab-containing regimens
depending on ER and HER2 status of the tumours, suggesting
heterogeneous biological characteristics8–11. Furthermore, the
presence of additional molecular alterations, such as mutations of
PI3 kinase or PTEN phosphatase, also has an impact on this
response12–16. Thus, HER2-positive breast cancers vary in their
genome alterations, gene expression programs, and cell-of-origin
and this impacts on their microenvironment17,18, prognosis and
response to treatment. A comprehensive analysis of HER2-
positive tumour genomes should provide a definite basis for
understanding this heterogeneity and the natural history of
HER2-positive breast cancer and should help progress in the
management of patients with HER2-positive tumours.
Here as part of the ICGC Breast Cancer Working Group effort,
we have established gene expression profiles of 99 HER2-positive
breast tumours and the complete genomes of a subset of 64 tumours
were sequenced. A thorough analysis of this data set identifies
four expression groups each of which exhibits distinctive genomic
features such as mutations, copy-number variations (CNVs) or
structural variations. Moreover, our results lead to a refined ERBB2
amplicon of 106 kb and show that some amplifications are
compatible with a breakage–fusion–bridge (BFB) mechanism.
Results
Delineating four expression groups. A total of 289 HER2-
positive (HER2þ ) BCs with frozen tumour samples identified
from the French PHARE/SIGNAL programs19,20 were analysed.
HER2, ER and PR statuses were defined according to ASCO/CAP
guidelines21 (Methods). All cases were reviewed by breast
pathologists and corresponding DNA and RNA samples were
subjected to extensive quality controls (Methods). A total of 99
selected tumours were analysed for genome-wide expression
profiles, out of which 64 tumours and matched normal DNA
were subjected to whole-genome sequencing (WGS)
(Supplementary Data 1).
An unsupervised hierarchical cluster analysis of the 99
HER2þ samples delineated four main groups of gene expression,
herein referred to as A, B, C and D (Supplementary Fig. 1),
validated on two external data sets22,23 (Methods). In addition,
these 99 samples were assigned to PAM50 intrinsic subtypes24,
using an external data set25 of 537 expression profiles that
includes the whole spectrum of the BC disease and was
hybridized on the same experimental platform to minimize
technical biases (Methods).
Groups A and B were mostly composed of ERþ and luminal B
tumours while ER- and HER2-enriched tumours were mostly
observed in groups C and D (Table 1). Group D encompassed all
(n¼ 6) basal tumours. As expected, ESR1, PGR and ERBB2 genes
expression levels were tightly correlated with ER, PR and HER2
statuses, respectively, and decreased from groups A to D. Gene
sets specific to the mammary stem cells (MaSCs), luminal
progenitor (pLum) and luminal mature (mLum) populations26
were analysed, showing an increasing expression gradient from
groups A to D for pLum and a corresponding decreasing gradient
for mLum (Supplementary Fig. 2a–c).
Distinctive genomic features of expression groups. A total of
554,554 somatic mutations (549,003 single-nucleotide variations
(SNVs) and 5,551 small insertions and deletions (indels)) were
detected in the 64 tumours (Methods). The median mutation
frequency was 1.95 per Mb (range 0.55–35.34 per Mb) in
agreement with previous BC estimates27,28 (Supplementary
Fig. 3). A total of 7,090 somatic mutations (1.3%) were located
within coding exons, including 5,194 (73%) non-silent mutations
in 3,845 different protein-coding genes. We identified 305
homozygous gene deletions (HD) (Methods) in 295 different
genes. In total, 4,086 genes were altered (SNV or HD) in at least
one tumour (Supplementary Data 2) and 52 genes in at least four
tumours. Eight out of these 52 genes are known to be involved in
cancer: TP53, PIK3CA, JAK2, ATRX, MAP2K4, ERBB2, KMT2C
and KMT2D. TP53 mutations were present in 28 (44%) tumours,
including 21 missense mutations, 4 truncating mutations and 2
mutations altering splice junctions. TP53 mutations were
present in both ERþ and ER cases, although more frequent
in ER than ERþ tumours (P¼ 5 10 3, Fisher’s exact test),
and HER2-enriched and basal than luminal subtypes
(P¼ 5 10 6, Fisher’s exact test) as previously observed29,30.
Striking differences appeared when considering the four
gene-expression groups (P¼ 7 10 10, Fisher’s exact test).
Group A was devoid of TP53 mutations while all group
D tumours were mutated (Fig. 1). PIK3CA displayed only
missense mutations (18 mutations in 17 tumours), including 11
Table 1 | Associations between RNA expression groups
and biological characteristics for the 99 samples of the
INCa-HER2þ data set.
RNA group Total
A B C D
No. of samples 29 28 22 20 99
ERþ (ER ) 28 (1) 27 (1) 7 (15) 5 (15) 67 (32)
PRþ (PR ) 19 (8) 24 (3) 2 (20) 3 (17) 48 (48)*
HER2 IHC 3þ (2þ ) 16 (13) 23 (5) 20 (2) 16 (4) 75 (24)
PAM50
Luminal A 2 1 0 0 3
Luminal B 27 23 4 1 55
Her2-enriched 0 4 18 13 35
Basal 0 0 0 6 6
Whole-genome seq. 21 17 12 14 64
*Three cases with unknown PR status.
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hotspot mutations (Supplementary Data 2). MAP2K4 displayed
HD in three ERþ cases and GATA3 displayed three frameshifts.
Six ERBB2 missense mutations were observed in four tumours
including two in the kinase domain31. To assess if modifications
of potential cis-regulatory regions could also contribute to
differences between the four expression groups, we studied
somatic SNVs in these regions by looking at a combination of
histone marks enriched in regulatory region and FANTOM5
enhancer and promoter annotation32 (Methods). An under-
representation of SNVs located in H3K4me1 and H3K27ac
enhancers was observed in ERþ tumours (P¼ 8 10 3, Mann–
Whitney U-test) and in group A (P¼ 8 10 3, Kruskal–Wallis
test; P¼ 6 10 4, Mann–Whitney U-test, A versus BCD)
(Supplementary Fig. 2d,e).
Somatic CNVs were derived from WGS for the 64 sequenced
tumours (Methods). CNV frequency profiles (Supplementary
Fig. 4) were in good agreement with published profiles33,34 of
HER2þ tumours including the ERBB2 amplicon as well as
recurrent CNVs found in BCs. Some CNVs were group specific:
gains of 2p and 2q chromosomal arms were more frequent in
group D (P¼ 1 10 3 and 3 10 3, respectively, Fisher’s exact
test), while loss of 11q was more frequent (P¼ 5 10 3, Fisher’s
exact test, FDR corrected) and loss of 14q was less frequent
(P¼ 1 10 2, Fisher’s exact test, FDR corrected) in group A.
The median fraction of the genome altered (FGA) was 59%, a
number somewhat higher than previously reported by using
array-CGH33 (34%). FGA was lower in group A than in the three
other groups (P¼ 2 10 2, Kruskal–Wallis test; P¼ 2 10 3,
Mann–Whitney U-test, A versus BCD) (Supplementary Fig. 2f).
As already reported33, other regions from 17q were found to be
amplified including the 17q21.32-17q21.33 region that harbours
SPOP (amplified in 14% of the tumours) and KAT7 (20%) genes
as well as the 17q23.1-17q24.3 region that harbours RPS6KB1
(25%), PPM1D (27%), BCAS3 (20%) and DDX5 (16%) genes.
These two regions appeared more frequently amplified in group
A (Supplementary Fig. 5). High-level gene amplifications were
observed on chromosomes 8, 11 and 20 in more than 10% of the
patients and on chromosomes 1, 6 and 12 in 5–10% of the
patients (Supplementary Fig. 6). These regions included several
known or putative oncogenes (Supplementary Data 3): 8p11.23
(ZNF703 (17%), WHSC1L1 (11%), FGFR1 (11%) and PPAPDC1B
(9%); 8q23.1 (RSPO2 (16%) and EIF3E (14%)); 8q24.11 (RAD21
(16%)); 8q24.21 (MYC (19%)); 11q13.3 (CCND1 (22%)); 20q13.2
(ZNF217 (11%)). Amplification of PPM1D and CCND1 was more
frequent in group A than in the other groups (P¼ 2 10 3 and
4 10 3, respectively; Fisher’s exact test, FDR corrected).
A total of 133 firestorms35 (Methods) were detected in 27
different chromosomal arms in 58 patients (90%). Although
firestorms were observed at least once in all chromosomal arms,
they were more frequent in 17q (n¼ 41 tumours); 8q (n¼ 18)
and 11q (n¼ 10).
A total of 24,203 somatic structural variations (SVs)
were detected (Methods), with a median of 327 per sample
(range 132–952) in agreement with the reported values36. The
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Figure 1 | Summary of biological and genomic features of the 64 sequenced HER2þ tumours. (a) (From top to bottom) RNA expression groups; PAM50
subtypes; ER, PR and HER2 IHC statuses; HER2 CNV status; estimated ploidy; Fraction of genome altered (FGA) quartiles; number of large scale transitions
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12222 ARTICLE
NATURE COMMUNICATIONS | 7:12222 |DOI: 10.1038/ncomms12222 | www.nature.com/naturecommunications 3
majority (75%) of these variants were intra-chromosomal
(Supplementary Fig. 7) and composed of 7,438 (41%) inversions,
5,889 (33%) deletions and 4,731 (26%) duplications. The numbers of
intra- and inter-chromosomal SVs were correlated (Kendall
tau¼ 0.46, P¼ 7 10 8, Kendall’s test). Intra-chromosomal SVs
were more frequent on chromosome 17 with a median of 30.5 SVs
than on all other chromosomes (median of 6.0; Po1 10 10,
Mann—Whitney U-test). Although no association was observed
between the number of SVs on chromosome 17 and ER status,
RNA groups A and C displayed more intra-chromosomal SVs
on chromosome 17 than groups B and D (P¼ 4 10 3,
Mann—Whitney U-test for AC versus BD; Supplementary Fig. 8).
The most frequent inter-chromosomal rearrangements were
observed between pairs of chromosomes (17 and {8, 11}); (1 and
{2, 3, 5, 6, 8}) and (8 and 6). ER tumours displayed more scattered
inter-chromosomal rearrangements than ERþ tumours. More
specifically, RNA group A displayed focused rearrangements,
mostly limited to (17 and {8, 11}) and (1 and {2, 6}), while RNA
group D displayed the most scattered pattern (Supplementary Fig. 9).
The number of inter-chromosomal rearrangements in a sample was
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Figure 2 | Examples of CNV patterns in the ERBB2 amplicon. X axis: position on chromosome 17, the minimal region defining the ERBB2 amplicon is
indicated by the blue shaded box. Y axis: tumoral integer copy number, computed in 1 kb binned read counts (Methods). Horizontal red segments indicate
the closest sequence consistent with a breakage fusion bridge (BFB) fold and the purple curved line represents the corresponding folding pattern.
Vertical lines indicate the location of detected breakpoints from discordant and clipped read pairs (Methods); plain lines correspond to intra-chromosomal
events and dashed lines to inter-chromosomal events; line colour (and glyph on the bottom) correspond to the clipped reads orientation, red (o): reads
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associated with the presence of a TP53 mutation (P¼ 5 10 2,
Mann–Whitney U-test). The homologous recombination deficiency,
measured by computing a BRCAness score as previously reported37
(Methods), was increasing from RNA groups A through
D (Supplementary Fig. 2g).
The ERBB2 amplicon. Using precise CNV levels as well as SV
breakpoints from WGS data allowed us to delineate precisely the
17q12 ERBB2 amplicon as a 106-kbp region (chr17:37818020-
37924454, GRCh37 build) that was amplified or gained in all the
samples, thus refining the 248-kbp region (chr17:37725640-
37973561) previously determined using array-CGH33. The
ERBB2 amplicon included six genes: TCAP, PNMT, PGAP3,
ERBB2, MIEN1 and GRB7.
In several tumours, the CNV patterns as well as the clipped
read orientations were consistent with a BFB mechanism. BFB is a
DNA amplification mechanism that has been discovered in maize
in the late 30s (ref. 38) but later evidenced in tumours39–41. It
occurs when a chromosome undergoes a double-strand break
(Supplementary Fig. 10a) followed by the erroneous fusion of the
two loose ends of the sister chromatids during replication. This
results in the formation of a bridged dicentric chromosome that is
torn apart during the next anaphase (Supplementary Fig. 10b),
inducing a further breakage that will repeat the process. At each
cycle, stretches of DNA close to the breakpoints are duplicated
head to head leading to the exponential accumulation of
palindromic sequences in the region containing breakpoints
(Supplementary Fig. 10c). When mapped to the reference
chromosome, these sequences will adopt a typical fold-back
structure that is the hallmark of BFB. The process stops when the
loose telomere is capped or fused to another chromosome to
produce a translocation. In terms of sequence data there are two
main hallmarks of BFB process. First the copy-number pattern
follows some specific sequences42,43 (Supplementary Fig. 10d),
that is, not all possible discrete values are allowed. Second, when
using paired-end sequencing, read pairs with discordant
orientations mark the vicinity of breakpoints. In addition, reads
spanning breakpoints may be clipped to the right or to the left
depending on the direction of the fold. Therefore, the orientation
of discordant pairs and clipped reads provide additional clues to
characterize a BFB fold. Figure 2a–c gives three examples of such
patterns, consistent with a BFB mechanism for ERBB2
amplification39. In some cases (Fig. 2c) several breakpoints were
associated with inter-chromosomal events, suggesting that the
amplification may have taken place on other chromosomes. We
also observed patterns that are very unlikely to have occurred by a
BFB process, such as the focal amplification depicted in Fig. 2d,
suggesting that other mechanisms may also be involved in ERBB2
gene amplification such as the formation of double-minutes
chromosomes44. Finally, some intricate fold patterns may also
suggest that several mechanisms may sometimes combine at the
same locus.
Discussion
We used gene expression as an operational basis to classify
HER2þ tumours into four groups that were further character-
ized in terms of interdependent genomic variables. A synoptic
outline of the dependencies between these variables, provided by
multiple correspondence analysis (MCA) (Methods) is shown on
Fig. 3. Groups A and B were ERþ tumours, harboured genomic
alterations observed in luminal BCs and were close to the luminal
B intrinsic subtype. Main features of group A (left part of Fig. 3)
were the absence of TP53 mutations, low FGA, higher number of
SVs on chromosome 17 and specific amplifications in CCND1
(11q13) and RPS6KB1 (17q23) regions. In contrast, tumours in
groups C and D were mostly ER and close to the HER2-
enriched intrinsic subtype. TP53 mutations were frequent in these
groups and analysis of genome breakages showed higher FGA
and some pattern of BRCAness. Moreover, analysis of the mLum
and pLum signatures suggested that A and B tumours derive from
differentiated mature luminal cells, while C and D derive from
luminal progenitors, like basal tumours. Altogether, these results
suggest that HER2þ BCs do not per se represent an actual
intrinsic subtype but, instead, are distributed along the whole BC
spectrum, from ERþ luminal to ER basal phenotype, with
genome alterations in accordance to these phenotypes and are
incidentally characterized by a specific gene amplification.
Although patients with HER2þ BC benefit from HER2-
targeted therapies, the response is highly variable and a significant
number of patients display primary or secondary resistance.
Heterogeneity of these cancers may explain the extent of this
variability. Thus, how important the molecular and cell-of-origin
definition of HER2 tumours may be to understand BC
oncogenesis, the prime interest of the medical community lies
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Figure 3 | Multiple correspondence analysis of selected biological and
genomic variables. Patients are represented by small grey dots and
variables (categories) are represented by coloured squares, triangles and
large dots. Categories indicated by triangles and squares were used for
MCA analysis whereas categories indicated by larger dots were just
projected on the resulting map. This map has a simple geometrical
interpretation: a category is plotted at the centre of gravity of the patient
points for those patients that choose that category (conversely, at a scaling
factor, patient points are located at the centre of gravity of categories they
choose). As an example, patients points have been linked to the RNA group
they belong to (grey ellipses). Therefore the proximity of two categories
suggests that they are chosen by a similar set of patients. Categories labels
are as follows: RNA groups (RNA.A, RNA.B, RNA.C and RNA.D); PAM50
subtypes (LumB, Her2, Basal); ER status (ER.POS, ER.NEG), PR status
(PR.POS, PR.NEG); TP53 mutations: (TP53.M, TP53.WT); fraction of
genome altered (FGA.L (lower quartile), FGA.H (upper quartile)); number
of interchromosomal SVs in chromosome 17 (SV17.L (lower quartile),
SV17.H (upper quartile)); Number of Large Scale Transitions (BRCAness
score) (LST.L (lower quartile), LST.H (upper quartile)); progenitor luminal
signature score (pLum.L (lower quartile), pLum.H (upper quartile)); mature
luminal signature score (mLum.L (lower quartile), mLum.H (upper
quartile)); for clarity, interquartile points are not plotted.
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in the therapeutic opportunity provided by the identification of
homogeneous subgroups and a better understanding of the
genetic mechanisms involved. Clinical follow-up of our cohort of
HER2þ tumours will determine the importance of splitting
HER2þ BCs in A to D groups.
Methods
Patient samples and ethical approval. A total of 289 female patients diagnosed
with HER2-positive breast cancer were recruited through the French PHARE/
SIGNAL trial19,20. The trial was sponsored by the French National Cancer Institute
(INCa), approved by the Central Ethical Committee (Comite´ de Protection des
Personnes, CHU Besanc¸on) on 15 May 2006. It was done in compliance with the
principles of Good Clinical Practice and the Declaration of Helsinki and registered
at ClinicalTrials.gov, number NCT00381901. Patients were eligible if they were
over 18 years of age with histologically confirmed invasive early breast cancer with
HER2 overexpression and had provided signed informed consent. For each patient,
tumour tissue as well as matched blood samples were collected. Tumours were
snap-frozen in liquid nitrogen upon surgical removal after pathologist’s review and
were stored in the corresponding hospital’s biological resources center. The clinical
HER2 status was assessed in accordance with the ASCO/CAP guidelines21. HER2
protein expression was scored by performing immunohistochemistry (IHC) on a
tumour section from FFPE blocks for all patients. Cases displaying a 3þ score
were considered positive and cases only displaying a 2þ score were tagged as
equivocal. In equivocal cases, HER2 gene amplification status was further
determined using either fluorescence in situ hybridization (FISH) or chromogenic
in situ hybridization (CISH) and only those showing an HER2 gene amplification
were then considered positive. ER and PR statuses were also established using IHC.
Breast pathologists reviewed all cases for ER, PR and HER2 status. Corresponding
pathological, clinical and follow-up data were obtained from the INCa PHARE/
SIGNAL clinical database.
Sample extraction. Samples had full face sectioning performed in with Tissue-Tek
optimal cutting temperature (O.C.T) compound to estimate the percentage of
malignant epithelial nuclei in the sample relative to stromal nuclei. Macrodissec-
tion was performed if required to excise areas of non-malignant tissue. DNA and
RNA were then extracted from the same sample. Total genomic DNA was
extracted with phenol-chloroform after proteinase K digestion, followed by the
precipitation of nucleic acids in ethanol. DNA was quantified using Nanodrop
spectrophotometer ND-1000 (ThermoScientific, Wilmington, USA) and Qubit BR
DNA assay (Invitrogen). RNA was also extracted using the miRNeasy miniKit
(Qiagen) in accordance to the manufacturer’s protocol. RNA was quantified using
Nanodrop spectrophotometer ND-1000 and the purity and integrity were assessed
by the Agilent 2100 Bioanalyzer and RNA 6000 Nano Labchip Kit (Agilent Bio-
technologies, Palo Alto, CA, USA). All matched peripheral bloods have been
centralized and then extracted using the salting-out method with a Qiagen
Autopure LS (Courtaboeuf, France) in the Fondation Jean Dausset CEPH
laboratory. To confirm the matching between tumour and blood DNA issued from
a same patient, the AmpFLSTR Identifiler PCR Amplification Kit (Life Technol-
ogies) has been used.
Selection of high-quality HER2-positive samples. A total of 289 tumour samples
(and matched blood samples) were processed as described in the previous section.
A special attention was then paid to the selection of a high-quality subset of these
samples for further analysis. Proportion of tumour cells were estimated on frozen
tumour sections by pathologists and only those estimated with at least 50% tumour
cells were kept. All DNA and RNA samples were subjected to quality controls
(RNA integrity number Z7; DNA integrity checked on agarose gel) leaving a
subset of 131 samples. The tumour DNAs of these 131 patients were hybridized on
Illumina OmniExpress arrays to establish the genomic profile of each tumour.
These genomic profiles were used to control the presence of the ERBB2 gene
amplification and to obtain another estimation of the tumour purity (see SNP array
processing section below for details). A missing ERBB2 amplification/gain or a very
low estimated purity caused the sample to be discarded. At the end of the process,
99 samples (hereafter called the INCa-HER2þ data set) met the required quality
criteria, out of which 64 were subjected to WGS.
Gene expression array processing and quality control. Tumour RNA samples
were analysed for expression profiling on Affymetrix U133 Plus 2.0 GeneChip.
Quality control was asserted by using R package affyPLM45. Raw feature data were
normalized using robust multi-array average46 method in R package affy47. Probe
sets corresponding to control genes were filtered out.
PAM50 subtypes classification. Each tumour gene expression profile from the
INCa-HER2þ data set was assigned to a PAM50 breast molecular subtype24. The
PAM50 classifier was built using a training cohort, which aims at capturing the
major breast cancer types in the general population. As the INCa-HER2þ data set
was exclusively composed of HER2þ samples, the underlying distribution of
expression profiles was likely to be not representative of the whole spectrum of
breast cancers expression profiles48. To overcome this difficulty, we collected 537
Affymetrix expression profiling of all types of breast cancers from the Carte
d’Identite´ des Tumeurs (CIT) project25 from the French Ligue Nationale Contre le
Cancer. This cohort was hybridized on the same microarray and on the same
experimental platform (at IGBMC Strasbourg) than the INCa-HER2þ data set,
thus minimizing technical biases. The CIT data set is available on ArrayExpress
under accession number E-MTAB-365. First, all expression profiles from CIT and
INCa-HER2þ data sets were normalized together using the robust multi-array
average method46 as above. Then, to maintain the relative proportions of the
PAM50 subtypes, each of the 99 INCa-HER2þ samples was included one by one
into the CIT data set and assigned to a PAM50 subtype using the R package
genefu49 v1.12.0 with robust scaling of the gene expressions centroids.
Unsupervised clustering of transcriptomic array profiles. The clustering of
transcriptomic array profiles was performed in two steps. The first step aims at
selecting probesets carrying the most differential expression across the data set.
This was done by using two criteria: (a) for each probeset, we tested whether its
variance across samples was different from median of the variances of all the
probesets. The statistics and criterion used were the same as in the filtering tool of
BRB ArrayTools software50, where the variance to median ratio is compared with a
percentile of the chi-square distribution. Only probesets satisfying a P value of this
variance testo10 3 were kept. (b) In addition, probesets were ordered by relative
s.d. and the top 5% percentile was retained. After this step, we were left with 274
probesets corresponding to 196 known genes. The second step was an
agglomerative hierarchical clustering using Pearson correlation as a similarity
measure and the Ward’s minimum variance linkage method.
Validation of RNA groups on TCGA and Metabric HER2þ data sets. Two
publicly available expression profiling data sets were collected for validation pur-
pose. The first one was the Breast Invasive Carcinoma (BRCA) collection of 1,098
tumours from TCGA22. We selected the subset of 114 samples defined as HER2þ
in the original paper, out of which 75 had associated Agilent G4502A microarray
expression data. The second validation set came from the Metabric breast cancer
collection23. We selected a subset of 122 HER2-amplified tumours with IHC status
equal to 2þ or 3þ and copy number of ERBB2 locus gained according to SNP6
array (no IHC-FISH status was available in this data set). Raw Illumina HT-12-v3
expression profiling data were obtained after data access authorization and
normalized using R package beadarray51. To allow the comparison between
expression data from different array technologies, we reduced the RNA group
signature defined with probesets to genes by using the best genes according to
JetSet52. This resulted in 196 genes out of which 162 and 180 were defined in
TCGA and Metabric data respectively.
We used two different and complementary methods for validation on both sets.
The first method is a single sample predictor (SSP) method. First the centroid of
each RNA group (labelled A, B, C, D) was computed on the centred-reduced INCa
data set. Then, for each single external sample (that is, from TCGA or Metabric),
we computed the Spearman rho correlation coefficient with each of these centroids
and the sample was assigned to the RNA group with the largest correlation
coefficient or to no group (O) if the correlation coefficient was o0.1.
Independently, the whole external data set was clustered into four clusters (labelled
1, 2, 3, 4) using the same agglomerative hierarchical clustering method as before.
The stability of the RNA groups in the external data set was then evaluated by
examination of the (A, B, C, D, O) (1, 2, 3, 4) contingency table and practically
measured by the fraction of the most abundant RNA label in each cluster (that is,
100% if all clusters are composed of a single RNA group and, about 25% if RNA
groups are spread randomly across clusters). The second method (joined) consisted
in merging the independently centred-reduced INCa and external data sets. This
joined set was then clustered into four clusters (labelled 1, 2, 3, 4) using the same
agglomerative hierarchical clustering method as before and the stability of the RNA
groups was then evaluated by examination of the (A, B, C, D)  (1, 2, 3, 4)
contingency table of the data reduced to the INCa-HER2 subset (that is, for which
the actual RNA group labels are known). A RNA group label can further be
assigned to each of the four clusters (by considering the majority label in the INCa-
HER2 subset) and, eventually, to each external sample. Finally, for both methods,
clinical and biological metadata (namely ER status, PAM50 subtypes and P53
mutation status) per RNA group were also compared.
Results are shown in Supplementary Figs 11 15. Supplementary Fig. 11
displays the RNA groups obtained on the original INCa-HER2 data set using all of
the 196 probesets as the reference. Supplementary Figs 12 and 13 (resp. 14 and 15)
displays the results obtained on the TCGA (resp. Metabric) data set for both SSP
and joined methods. The two methods gave similar results, with 76% (TCGA) and
81% (Metabric) of samples classified in the same RNA group by both methods. The
overall stability of RNA groups is good (80% (SSP), 75% (joined) for TCGA and
66% (SSP), 73% (joined) for Metabric). Groups A and D appeared more stable than
B and C. Finally, in terms of metadata, the same general features were observed for
the three data sets: (a) over-representation of ERþ (resp. ER ) in groups A and B
(resp. C and D); over-representation of luminal B (resp. HER2-enriched and basal)
in groups A and B (resp. C and D). As for TP53 mutations, the situation is less
clear-cut: the under-representation of TP53 mutations in group A is observed both
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for INCa and TCGA data sets but is not significant for the Metabric data set.
However it should be pointed out that (a) this data set exhibits a lot of TP53
undetermined cases (51%) and (b) for determined cases the fraction of TP53
mutated cases is unusually low (28% versus 44% and 47%, respectively in INCa and
TCGA data sets).
Finally, all cases in the present study were included in the PHARE/SIGNAL
cohorts (NCT00381901-RECF1098, www.e-cancer.fr) with a median follow-up at
58 months (interquartile range 46.5–62.5). In this smaller subset and on this
period, recurrence events were very limited (4 out of all 99 cases) and the
relationship between RNA groups and outcome could not be analysed.
Gene expression signature projection. Gene signatures for mammary stem cell,
progenitor and mature luminal26 were projected by using the single sample
extension of GSEA53 where gene expression values for each single sample were
rank-normalized, and an enrichment score was produced using the empirical
cumulative distribution functions of the genes in the signature and in the
remaining genes.
SNP array processing. Illumina Omni1 Quad and OmniExpress SNP arrays
quality control and normalization was performed using GenomeStudio Genotyping
Module. A supplementary normalization step was applied using the tQN algo-
rithm54. Allelic CNVs were analysed using GAP55 and ASCAT 2.0 (ref. 56).
Tumour purity was estimated using both approaches, with a good correlation,
although GAP estimates were found to be always above ASCAT estimates
(Supplementary Fig. 16a). This allowed correcting these estimates by using their
geometric mean (Supplementary Fig. 16b). Estimates provided by pathologists were
systematically above all others and were not used for the final estimation. Ploidy
was estimated by using DNA indexes provided by the two methods and few
discrepancies were resolved by nearest neighbours clustering (Supplementary
Fig. 17). It should be noted that although DNA index of diploid tumours was
centred around 1.1, DNA index of aneuploid tumours was centred on 1.7, therefore
these tumours were probably resulting from a tetraploidisation event followed by
chromosomal losses.
Sequencing and genome alignment. WGS was performed on 64 tumours and
matched normal DNA from the same individuals. Tumour and normal DNAs were
sequenced to445-fold and 430-fold coverage, respectively. Illumina HiSeq2000/
HiSeq2500 genome analysers and Illumina paired-end sequencing protocols were
used for all samples, read lengths ranging from 100 to 126 base pairs. Paired-end
reads were aligned to the human genome (GRCh37) using the BWA aligner57.
Alignments were refined using GATK58 and Picard (http://broadinstitute.github.io/
picard/) software suites. Duplicates were removed from the sample BAM files for
further analysis. Raw and mapped sequences from all produced HiSeq lanes were
checked using in-house pipelines that collect a set of important metrics reflecting
the overall quality of the sequencing data. Lanes showing poor quality were
manually discarded.
SNV variant calling. Somatic SNVs were called using MuTect59 v1.1.5 part of the
GATK suite. To improve performance, data from dbSNP Build 132 and COSMIC
v65 (http://www.sanger.ac.uk/genetics/CGP/cosmic/) were supplied as parameters
to MuTect. On top of this, we used in-house post-processing filters to improve the
specificity of mutation calls. These filters include adjustments on strand bias, local
coverage, position of alternate allele within the read, mapping quality, repeated
regions. Moreover, a panel of normal genomes, generated on the same sequencing
technology, was used to dismiss systematic sequencing errors and/or low frequency
polymorphisms. SNV that passed all these filters were then annotated using the
variant effect predictor60 tool v75.
Mutations in cis-regulatory regions. Annotation of somatic variants that are
located in cis-regulatory regions was performed using OncoCis32, based on human
mammary epithelial cell epigenomic data sets. Annotated somatic variants were
further processed to classify those in potential promoter or enhancer regions.
Somatic SNVs in potential promoter regions were extracted if they localize around
H3K4me3 histone marks. Somatic variants in potential enhancer regions were
extracted if they localize around H3K4me1 or H3K27ac histone marks. In addition,
mutations were further annotated using FANTOM5 predictions61, which uses cap
analysis of gene expression to detect potentially active transcription from promotor
or enhancer regions. In both cases (promotors and enhancers regions) we
computed, per patient, the fraction of somatic SNVs located in these regions (that
is, number of SNVs in regions divided by the total number of SNVs in patient).
Copy-number analysis. The analysis of CNVs from whole-genome sequence data
was performed in three steps. First, after reads alignment using the Burrows-
Wheeler alignment tool (BWA), raw read counts at each genomic position were
corrected by GC content using the approach described by Benjamini and Speed62.
We slightly improved the construction of the empirical dependency model by using
only raw counts in mappable63 regions, by sampling positions (107) over the whole
genome and ignoring positions with extreme read counts. In a second step, the GC-
corrected relative read counts (rRC, defined as raw counts divided by predicted
counts) were computed within 1 kb windows in mappable regions and smoothed
along the chromosomes (Kalman filter) to get a well-resolved distribution of the
observed levels. This distribution was used to evaluate the tumour contamination
by normal DNA by fitting a sum of evenly spaced Gaussian peaks (the separation
between two consecutive peaks being equal to 1/(Qþ 2a(1 a)); with aA[0,1] the
contamination and Q the tumour mean ploidy). Finally, a univariate Gaussian
Hidden Markov Model (HMM, R package RHmm) was build, with parameters
(levels and variance) inferred from the previous step. This HMM was then used to
segment the GC-corrected relative read counts signal along the chromosomes. The
resulting segment levels are expressed as a relative tumoral CN (rCN)
corresponding to the states of the HMM, that is, rCN¼ 1, the reference CN state,
corresponds to the tumour mean ploidy (for example, 2 for a diploid tumour), 0.5
corresponds to the loss of half of the copies of the reference CN state (that is,
hemizygous state for a diploid tumour). These relative tumoral CN segments were
further used to define the gain/loss status of regions, using the following scale:
rCN43: amplification; 3ZrCN41: gain; rCNo1: loss; rCN¼ 0: homozygous
deletion.
Firestorms and large-scale transitions. A chromosome arm of high genomic
complexity and which harbours multiple closely spaced amplicons is said to be in
firestorm35. Using the CNV profiles computed from WGS data (see above) on each
tumour, a chromosome arm was claimed in state of firestorm if it had at least 20
genomic segments reaching at least 10 different levels of copy number and if,
among those segments, at least 5 were amplifications (rCN43).
Large-scale state transitions (LST) were defined37, as chromosomal break
between adjacent regions of at least 10Mb each. As suggested37, the number of
LSTs in the tumour genome was estimated for each chromosome arm
independently (not accounting for centromeric or unmappable regions breaks) and
after filtering and smoothing of all variations o3Mb.
Structural variants calling. Somatic SVs were identified by using two com-
plementary signals from read alignments: (a) discordant pair mapping (wrong read
orientations or insert-size larger than expected) and (b) soft-clipping (first or last
bases of read unmapped) that allows to resolve SV breakpoints at the base pair.
Each SV candidate was defined by a cluster of discordant pairs and one or two
clusters of soft-clipped reads. The discordant pairs cluster defined two associated
regions (possibly on different chromosomes) and the soft-clipped reads cluster(s),
located in these regions, specified the potential SV breakpoint positions. We further
checked that the soft-clipped bases at each SV breakpoint were correctly aligned in
the neighbourhood of the associated region. Events were then classified as germline
or somatic depending on their presence in the matched normal set of events.
Somatic SVs were further filtered according to several criteria: at least 2 discordant
read pairs per cluster; at least 2 soft-clipped reads per cluster; at least 15 aligned
clipped bases and at least 1 breakpoint should be located in a mappable region63.
Structural variants were then classified as intra-chromosomal event (deletion,
duplication, inversion) or inter-chromosomal (breakpoints on different
chromosomes) according to discordant read pairs type.
BFB amplification analysis. We used two independent sources of information for
testing the BFB amplification mechanism for the ERBB2 amplicon: the CNV
patterns and discordant read pairs and clipped reads orientation at breakpoints.
The main hallmark of BFB is that the CNV pattern follows some specific
sequences43,64. A technical difficulty is that this requires the determination of
tumoral absolute integer copy number (aCN), whereas NGS data primarily
provides relative read counts (rRC, see section ‘Copy-number analysis’); aCN
linearly relates to rRC as a function of the contamination by normal DNA and the
mean ploidy of the tumour. So we first determined precisely these two quantities by
plotting and fitting rRC versus allelic frequencies of SNPs over all the genome. We
then segmented the aCN profile by using the same HMM procedure as before
(section ‘Copy-number analysis’). Finally, we used the algorithm developed by
Zakov and Bafna42 to check if the observed aCN sequences were compatible with a
BFB sequence and/or to look for the longest compatible sequence. This is basically
the same approach used by Greenman et al.65. Another possible approach is to
estimate the rearrangement process and copy numbers simultaneously43. However,
the later approach has a risk of overfitting the data, especially for short sequences.
Therefore, except for one case (PI034), we did not readjust the predicted aCN levels
to fit with a BFB sequence. In the case of PI034, we had to shift the read count
signal by a constant value (2) to get a valid BFB sequence. This may be explained by
the presence of two copies of the homologous chromosome 17 in this tumour.
Beyond checking for the validity of a putative BFB sequence, the Zakov and Bafna
algorithm42 also provides the corresponding folding pattern (visually represented
by the purple curved line on illustrations provided in Fig. 2a c). This allows for
an additional and independent confirmation of the BFB fold. To this purpose we
superimposed the location of somatic SV breakpoints (see section ‘Structural
variant calling’) to the CN plot. Of course the curve should ideally fold at identified
breakpoints, but, more importantly, the folding pattern should fit with the clipped
reads orientation. More precisely, when the fold occurs to the left side, the reads
should be clipped on their right (3’) side (that is, they align on their left part) and,
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conversely, when the fold occurs to the right side, the reads should be clipped on
their left side. Therefore by simply colouring the breakpoint locations, we could
visually check if the clipped reads orientation was compatible with the proposed
BFB folding pattern. In all of the cases we examined, this test was always successful
therefore providing a strong support in favour of the hypothesis that the folding
pattern was indeed generated by a BFB mechanism.
Multiple correspondence analysis. MCA is a multivariate statistical approach
suited to the exploratory analysis of nominal categorical data66. It is an extension of
correspondence analysis when more than two variables are involved. It can also be
considered as an adaptation of principal component analysis (PCA) to nominal
(instead of quantitative) data, using the chi-square (instead of euclidean) metric.
Briefly, categorical variables are first encoded into boolean complete disjonctive
form. For instance the RNA group variable has four categories (A, B, C, D), a
patient in category A is therefore encoded as RNA.A¼ 1, RNA.B¼ 0, RNA.C¼ 0,
RNA.D¼ 0. Then this complete disjunctive table is submitted to standard
correspondence analysis using the ADE4 R package67 with Benze´cri correction68 of
the eigenvalues. Quantitative variables (for example, FGA) should be first encoded
to categorical. To this purpose, we use the upper, lower and interquartile categories.
The purpose of MCA is to construct a joint map of patients and variable categories
in such a way that a patient is close to a category it is in, and far from the categories
it is not in (conversely a category is close to the patients that have it and far from
patients that do not have it). This map has a simple geometrical interpretation69,
thanks to the centroid principle: MCA plots a category point at the centre of gravity
of the patient points for those patients that choose that category (conversely, at a
scaling factor, patient points are located at the centre of gravity of categories they
choose). Finally, it should be pointed out that beside variables categories used for
the analysis, it is also possible to project additional categories (or patients) onto the
map. The projected category is simply located at the centre of gravity of those
patients that choose this category.
Data availability. Raw data have been uploaded to the European Genome-phe-
nome Archive (EGA; http://www.ebi.ac.uk/ega) under the overarching study
accession number EGAS00001001431. This study includes all data from whole-
genome sequencing, genotyping arrays and gene expression arrays used in this
work. Access to whole-genome sequences and genotyping arrays is subjected to the
ICGC data access authorization (DAC: EGAC00001000010 and Policy:
EGAP00001000037). The CIT data set is available on ArrayExpress (http://
www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-365. METABRIC
expression data sets are available at EGA under study accession number
EGAS00000000083. TCGA expression data set is available on the TCGA data
portal (https://tcga-data.nci.nih.gov/docs/publications/brca_2012). The remaining
data are contained within the Article or Supplementary Information files, or
available from the authors upon request.
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